BeiGene Ltd - ADR

BeiGene Ltd - ADR

BGNE

Market Cap$20.21B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BeiGene Ltd - ADRBeiGene Ltd - ADR-69.7--25%-0.3

Earnings Call Q4 2024

February 27, 2025 - AI Summary

Strong Revenue Growth: BeiGene reported a full-year revenue of $3.8 billion for 2024, representing a 55% increase compared to $2.5 billion in 2023. The fourth-quarter revenue was $1.1 billion, showing a 77% year-over-year growth. BRUKINSA sales reached $828 million in Q4 alone, marking a notable 100% growth compared to the same period last year.
Guidance for 2025: The company expects revenue between $4.9 billion and $5.3 billion in 2025, driven by continued share gains for BRUKINSA in the U.S. market and expansion in Europe and other international markets. This is underpinned by a stable pricing environment and momentum from new patient starts, particularly as the company laps 2024's strong performance.
Hematology Franchise Leadership: BeiGene is positioning BRUKINSA as the preferred BTK inhibitor for CLL treatment, capturing over 50% of new patient share and achieving a significant lead in both frontline and relapsed/refractory cases. This success is attributed to BRUKINSA's superior profile compared to competitors like Calquence and IMBRUVICA.

Exclusive for Stockcircle Pro members

Sign upSign Up
$150.03

Current Fair Value

18.8% downside

Overvalued by 18.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$20.21 Billion
Enterprise Value$18.66 Billion
Dividend Yield$0 (0%)
Earnings per Share$-8.45
Beta0.63
Outstanding Shares0

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-69.74
PEG44.61
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue5.63
Enterprise Value to EBIT-20.78
Enterprise Value to Net Income-22
Total Debt to Enterprise0.06
Debt to Equity0.33

Revenue Sources

No data

Insider Trades

ESG Score

No data

About BeiGene Ltd

CEO: John Oyler